Mechanism of differentiation-enhanced photodynamic therapy for cancer: Upregulation of coproporphyrinogen oxidase by C/EBP transcription factors

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1638-1650

  Anand, Sanjay ^a   Hasan, Tayyaba ^b   Maytin, Edward V ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; CCAAT ENHANCER BINDING PROTEIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CCAAT ENHANCER BINDING PROTEIN DELTA; COPROPORPHYRINOGEN OXIDASE; PROTOPORPHYRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; CANCER THERAPY; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEOPLASM; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

ANIMALS; BASE SEQUENCE; BINDING SITES; CCAAT-ENHANCER-BINDING PROTEINS; CELL LINE, TUMOR; COPROPORPHYRINOGEN OXIDASE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASMS; PHOTOCHEMOTHERAPY; PROTEIN BINDING; PROTOPORPHYRINS; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84882275485     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0047     Document Type: Article

References (50)

1. Hasan T, Ortel B, Solban N, Pogue BW. Photodynamic therapy of cancer. In:Kufe D, Bast R, Hait W, et al., editors. Cancer medicine. 7th ed. Hamilton, ON, Canada: BC Decker, Inc.; 2006. p. 537-48.
2. Celli JP, Spring BQ, Rizvi I, Evans CL, Samkoe KS, Verma S, et al. Imaging and photodynamic therapy: Mechanisms, monitoring, and optimization. Chem Rev 2010;110:2795-838.
3. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: Basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-8.
4. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
5. Sinha AK, Anand S, Ortel BJ, Chang Y, Mai Z, Hasan T, et al. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer 2006;95:485-95.
6. Anand S, Ortel BJ, Pereira SP, Hasan T, Maytin EV. Biomodulatory approaches to photodynamic therapy for solid tumors. Cancer Lett 2012;326:8-16.
7. Ortel B, Sharlin D, O'Donnell D, Sinha AK, Maytin EV, Hasan T. Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells. Br J Cancer 2002;87:1321-7.
8. Anand S, Honari G, Hasan T, Elson P, Maytin EV. Low-dose methotrexate enhances aminolevulinate-based photodynamic therapy in skin carcinoma cells in vitro and in vivo. Clin Cancer Res 2009;15: 3333-43.
9. Sato N, Moore BW, Keevey S, Drazba JA, Hasan T, Maytin EV. Vitamin D enhances ALA-induced protoporphyrin IX production and photodynamic cell death in 3-D organotypic cultures of keratinocytes. J Invest Dermatol 2007;127:925-34.
10. Anand S, Wilson C, Hasan T, Maytin EV. Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy. Cancer Res 2011;71:6040-50.
11. Ortel B, Chen N, Brissette J, Dotto GP, Maytin E, Hasan T. Differentiation-specific increase in ALA-induced protoporphyrin IX accumulation in primary mouse keratinocytes. Br J Cancer 1998;77: 1744-51.
12. Duprez E, Wagner K, Koch H, Tenen DG. C/EBPbeta: A major PMLRARA-responsive gene in retinoic acid-induced differentiation of APL cells. EMBO J 2003;22:5806-16.
13. Lee YJ, Jones LC, Timchenko NA, Perrotti D, Tenen DG, Kogan SC. CCAAT/enhancer binding proteins alpha and epsilon cooperate with all-trans retinoic acid in therapy but differ in their antileukemic activities. Blood 2006;108:2416-9.
14. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, Croce M, et al. Differentiation therapy: Targeting human renal cancer stem cells with interleukin 15. J Natl Cancer Inst 2011;103:1884-98.
15. Umek RM, Friedman AD, McKnight SL. CCAAT-enhancer binding protein: A component of a differentiation switch. Science 1991;251: 288-92.
16. Lane MD, Tang QQ, Jiang MS. Role of the CCAAT enhancer binding proteins (C/EBPs) in adipocyte differentiation. Biochem Biophys Res Commun 1999;266:677-83.
17. Diehl AM, Michaelson P, Yang SQ. Selective induction of CCAAT/enhancer binding protein isoformsoccurs during rat liver development. Gastroenterology 1994;106:1625-37.
18. Schrem H, Klempnauer J, Borlak J. Liver-enriched transcription factors in liver function and development. Part II: The C/EBPs and D sitebinding protein in cell cycle control, carcinogenesis, circadian gene regulation, liver regeneration, apoptosis, and liver-specific gene regulation. Pharmacol Rev 2004;56:291-330.
19. Koschmieder S, Halmos B, Levantini E, Tenen DG. Dysregulation of the C/EBPalpha differentiation pathway in human cancer. J Clin Oncol 2009;27:619-28.
20. Maytin EV, Habener JF. Transcription factors C/EBPalpha, C/EBPbeta, and CHOP (Gadd153) expressed during the differentiation program of keratinocytes in vitro and in vivo. J Invest Dermatol 1998;110:238-46.
21. OhHS, Smart RC. Expression of CCAAT/enhancer binding proteins (C/EBP) is associated with squamous differentiation in epidermis and isolated primary keratinocytes and is altered in skin neoplasms. J Invest Dermatol 1998;110:939-45.
22. Bundy LM, Sealy L. CCAAT/enhancer binding protein beta (C/EBPbeta)-2 transforms normal mammary epithelial cells and induces epithelial to mesenchymal transition in culture. Oncogene 2003;22: 869-83.
23. Sterneck E, Zhu S, Ramirez A, Jorcano JL, Smart RC. Conditional ablation of C/EBP beta demonstrates its keratinocyte-specific requirement for cell survival and mouse skin tumorigenesis. Oncogene 2006;25:1272-6.
24. Oh WJ, Rishi V, Orosz A, Gerdes MJ, Vinson C. Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas. Cancer Res 2007;67:1867-76.
25. Maytin EV, Lin JC, Krishnamurthy R, Batchvarova N, Ron D, Mitchell PJ, et al. Keratin 10 gene expression during differentiation of mouse epidermis requires transcription factors C/EBP and AP-2. Dev Biol 1999;216:164-81.
26. Schwartz PM, Barnett SK, Atillasoy ES, Milstone LM. Methotrexate induces differentiation of human keratinocytes. Proc Natl Acad Sci U S A 1992;89:594-8.
27. Ikezoe T, Gery S, Yin D, O'Kelly J, Binderup L, Lemp N, et al. CCAAT/enhancer-binding protein delta: A molecular target of 1,25- dihydroxyvitamin D3 in androgen-responsive prostate cancer LNCaP cells. Cancer Res 2005;65:4762-8.
28. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
29. Takahashi S, Taketani S, Akasaka JE, Kobayashi A, Hayashi N, Yamamoto M, et al. Differential regulation of coproporphyrinogen oxidase gene between erythroid and nonerythroid cells. Blood 1998;92:3436-44.
30. Pogulis RJ, Vallejo AN, Pease LR. In vitro recombination and mutagenesis by overlap extension PCR. Methods Mol Biol 1996;57: 167-76.
31. Johnson PF. Identification of C/EBP basic region residues involved in DNA sequence recognition and half-site spacing preference. Mol Cell Biol 1993;13:6919-30.
32. Osada S, Yamamoto H, Nishihara T, Imagawa M. DNA binding specificity of the CCAAT/enhancer-binding protein transcription factor family. J Biol Chem 1996;271:3891-6.
33. Miller M, Shuman JD, Sebastian T, Dauter Z, Johnson PF. Structural basis for DNA recognition by the basic region leucine zipper transcription factor CCAAT/enhancer-binding protein alpha. J Biol Chem 2003;278:15178-84.
34. Orkin SH. Differentiation of murine erythroleukemic (Friend) cells: An in vitro model of erythropoiesis. In Vitro 1978;14:146-54.
35. Tanabe A, Furukawa T, Ogawa Y, Yamamoto M, Hayashi N, Tokunaga R, et al. Involvement of the transcriptional factor GATA-1 in regulation of expression of coproporphyrinogen oxidase in mouse erythroleukemia cells. Biochem Biophys Res Commun 1997;233:729-36.
36. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, et al. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 1998;26:362-7.
37. Faisst S, Meyer S. Compilation of vertebrate-encoded transcription factors. Nucleic Acids Res 1992;20:3-26.
38. Ron D, Habener JF. CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription. Genes Dev 1992;6:439-53.
39. McKnight SL. CCAAT/enhancer binding protein. In:McKnight SL, Yamamoto KR, editors. Transcriptional regulation. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1992. p. 771-95.
40. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res 2007;67:11272-83.
41. Carey M. The enhanceosome and transcriptional synergy. Cell 1998;92:5-8.
42. Panne D. The enhanceosome. Curr Opin Struct Biol 2008;18:236-42.
43. Reeves R. Molecular biology of HMGA proteins: Hubs of nuclear function. Gene 2001;277:63-81.
44. Ripple MO, Henry WF, Schwarze SR, Wilding G, Weindruch R. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J Natl Cancer Inst 1999;91: 1227-32.
45. Huang PH, Wang D, Chuang HC, Wei S, Kulp SK, Chen CS. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis. Carcinogenesis 2009;30:1125-31.
46. Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: Involvement of NFkappa B, AP-1, and C/EBP. J Immunol 2003;170:3099-108.
47. Foti D, Iuliano R, Chiefari E, Brunetti A. A nucleoprotein complex containing Sp1, C/EBP beta, and HMGI-Y controls human insulin receptor gene transcription. Mol Cell Biol 2003;23:2720-32.
48. Kagan BL, Henke RT, Cabal-Manzano R, Stoica GE, Nguyen Q, Wellstein A, et al. Complex regulation of the fibroblast growth factor-binding protein in MDA-MB-468 breast cancer cells by CCAAT/enhancer-binding protein beta. Cancer Res 2003;63:1696-705.
49. Vallejo M, Ron D, Miller CP, Habener JF. C/ATF, a member of the activating transcription factor family of DNA-binding proteins, dimerizes with CAAT/enhancer-binding proteins and directs their binding to cAMP response elements. Proc Natl Acad Sci U S A 1993;90:4679-83.
50. Diehl JA, Hannink M. Identification of a C/EBP-Rel complex in avian lymphoid cells. Mol Cell Biol 1994;14:6635-46.